GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
September 06, 2023 08:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its...
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
August 21, 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the...
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2023 20:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of August 8,...
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023 16:05 ET
|
GeneDx Holdings Corp.
Accelerated whole exome and genome test volume growth by 56% year-over-year Total revenue of $48M in Q2 is inclusive of 36% year-over-year growth of exome and genome test revenue Expanded gross...
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
August 07, 2023 08:00 ET
|
GeneDx Holdings Corp.; PacBio
MENLO PARK, Calif. and STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a...
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
July 19, 2023 07:05 ET
|
GeneDx Holdings Corp.
NEW YORK and STAMFORD, Conn., July 19, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, and Prognos Health, the largest...
GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
July 18, 2023 16:05 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium
June 28, 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new...
GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants
June 26, 2023 16:01 ET
|
GeneDx Holdings Corp.
New paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyzing complex regions of the human pangenome Recently released human pangenome better represents...
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
June 20, 2023 07:00 ET
|
GeneDx Holdings Corp.
STAMFORD, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, applauds the decisions by the states...